1. Home
  2. SCLX vs WIMI Comparison

SCLX vs WIMI Comparison

Compare SCLX & WIMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SCLX
  • WIMI
  • Stock Information
  • Founded
  • SCLX 2011
  • WIMI 2015
  • Country
  • SCLX United States
  • WIMI China
  • Employees
  • SCLX N/A
  • WIMI N/A
  • Industry
  • SCLX Biotechnology: Pharmaceutical Preparations
  • WIMI Computer Software: Prepackaged Software
  • Sector
  • SCLX Health Care
  • WIMI Technology
  • Exchange
  • SCLX Nasdaq
  • WIMI Nasdaq
  • Market Cap
  • SCLX 81.7M
  • WIMI 78.8M
  • IPO Year
  • SCLX N/A
  • WIMI 2020
  • Fundamental
  • Price
  • SCLX $0.48
  • WIMI $1.08
  • Analyst Decision
  • SCLX Strong Buy
  • WIMI
  • Analyst Count
  • SCLX 3
  • WIMI 0
  • Target Price
  • SCLX $11.33
  • WIMI N/A
  • AVG Volume (30 Days)
  • SCLX 184.3K
  • WIMI 970.1K
  • Earning Date
  • SCLX 12-24-2024
  • WIMI 01-01-0001
  • Dividend Yield
  • SCLX N/A
  • WIMI N/A
  • EPS Growth
  • SCLX N/A
  • WIMI N/A
  • EPS
  • SCLX N/A
  • WIMI N/A
  • Revenue
  • SCLX $50,833,000.00
  • WIMI $84,137,968.00
  • Revenue This Year
  • SCLX $32.77
  • WIMI N/A
  • Revenue Next Year
  • SCLX $50.71
  • WIMI N/A
  • P/E Ratio
  • SCLX N/A
  • WIMI N/A
  • Revenue Growth
  • SCLX 9.41
  • WIMI 19.25
  • 52 Week Low
  • SCLX $0.46
  • WIMI $0.61
  • 52 Week High
  • SCLX $2.63
  • WIMI $1.87
  • Technical
  • Relative Strength Index (RSI)
  • SCLX 33.34
  • WIMI 67.61
  • Support Level
  • SCLX $0.48
  • WIMI $0.78
  • Resistance Level
  • SCLX $0.54
  • WIMI $1.02
  • Average True Range (ATR)
  • SCLX 0.06
  • WIMI 0.09
  • MACD
  • SCLX -0.00
  • WIMI 0.02
  • Stochastic Oscillator
  • SCLX 4.53
  • WIMI 77.54

About SCLX Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.

About WIMI WiMi Hologram Cloud Inc.

WiMi Hologram Cloud Inc and its subsidiaries offer augmented reality (AR) based holographic services and products to cater to its customers. Its AR service and product offerings primarily consist of holographic AR advertising services and holographic AR entertainment products. It is also into the semiconductor business, in which the company provides central processing algorithm services and computer chip products to enterprise customers and the sales of comprehensive solutions for central processing algorithms and related services with software and hardware integration. The company reports in three segments: AR advertising, AR entertainment, and Semiconductor. Its geographical segments are Mainland China, Hong Kong, and International.

Share on Social Networks: